Gambacorti-Passerini C - Search Results

1

Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase.

Mologni L, Tardy S, Zambon A, Orsato A, Bisson WH, Ceccon M, Viltadi M, D'Attoma J, Pannilunghi S, Vece V, Bertho J, Goekjian P, Scapozza L, Gambacorti-Passerini C. Mologni L, et al. ACS Omega. 2022 May 11;7(20):17083-17097. doi: 10.1021/acsomega.2c00507. eCollection 2022 May 24. ACS Omega. 2022. PMID: 35647450 Free PMC article.

2

In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.

Mologni L, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Biochem Biophys Res Commun. 1999 Oct 22;264(2):537-43. doi: 10.1006/bbrc.1999.1548. Biochem Biophys Res Commun. 1999. PMID: 10529398

3

Expression, purification, and inhibition of human RET tyrosine kinase.

Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Mologni L, et al. Protein Expr Purif. 2005 May;41(1):177-85. doi: 10.1016/j.pep.2005.01.002. Protein Expr Purif. 2005. PMID: 15802236

4

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.

Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA. Donella-Deana A, et al. Biochemistry. 2005 Jun 14;44(23):8533-42. doi: 10.1021/bi0472954. Biochemistry. 2005. PMID: 15938644

5

Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.

Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Coluccia AM, et al. Expert Opin Ther Targets. 2005 Jun;9(3):515-32. doi: 10.1517/14728222.9.3.515. Expert Opin Ther Targets. 2005. PMID: 15948671 Review.

6

An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase.

Gunby RH, Tartari CJ, Porchia F, Donella-Deana A, Scapozza L, Gambacorti-Passerini C. Gunby RH, et al. Haematologica. 2005 Jul;90(7):988-90. Haematologica. 2005. PMID: 15996942

7

A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.

Sala E, Mologni L, Cazzaniga S, Papinutto E, Gambacorti-Passerini C. Sala E, et al. Int J Biol Macromol. 2006 Aug 15;39(1-3):60-5. doi: 10.1016/j.ijbiomac.2006.01.006. Epub 2006 Feb 21. Int J Biol Macromol. 2006. PMID: 16490247

8

Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.

Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L. Gunby RH, et al. J Med Chem. 2006 Sep 21;49(19):5759-68. doi: 10.1021/jm060380k. J Med Chem. 2006. PMID: 16970400

9

Inhibition of RET tyrosine kinase by SU5416.

Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C. Mologni L, et al. J Mol Endocrinol. 2006 Oct;37(2):199-212. doi: 10.1677/jme.1.01999. J Mol Endocrinol. 2006. PMID: 17032739

10

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. Puttini M, et al. Cancer Res. 2006 Dec 1;66(23):11314-22. doi: 10.1158/0008-5472.CAN-06-1199. Epub 2006 Nov 17. Cancer Res. 2006. PMID: 17114238

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page